Aligos Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Aligos Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-24.0%

Rückkaufsrendite

Gesamte Aktionärsrendite	-24.0%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Jul 31

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Jul 16

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ALGS in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ALGS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Aligos Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ALGS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ALGS)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (ALGS) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ALGS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ALGS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ALGS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ALGS keine Ausschüttungen gemeldet hat.

Aligos Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 44%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analyst expectations

Aligos Therapeutics, Inc. Reports Recent Business Progress

Aligos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Price target decreased by 8.1% to US$103

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERald Study of ALG-055009 for the Treatment of MASH

New major risk - Share price stability

Consensus revenue estimates increase by 207%

Aligos Therapeutics Announces New Board Appointments

Second quarter 2024 earnings released: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Aligos Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aligos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Aligos Therapeutics, Inc. Announces Executive Changes

Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Aligos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Shareholder dilution

Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Second quarter 2023 earnings released: US$0.43 loss per share (vs US$0.47 loss in 2Q 2022)

Aligos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver (Easl) Congress 2023

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.84 loss in 1Q 2022)

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$2.84

Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

Price target decreased to US$2.55

Consensus revenue estimates increase by 43%

Aligos Therapeutics Presents Clinical Data for Its Capsid Assembly Modulator, Alg-000184, At Aasld’S the Liver Meeting® 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aligos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Aligos Therapeutics Initiates Dosing in Healthy Volunteers with siRNA Drug Candidate ALG-125755

Aligos Therapeutics, Inc. Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Consensus revenue estimates increase by 202%

Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.79 loss in 2Q 2021)

Aligos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aligos Therapeutics, Inc. Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating its Class II Capsid Assembly Modulator, ALG-000184

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell 2000 Growth Index

Aligos Therapeutics, Inc. to Participate in Metropolitan Antiviral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.74 loss in 1Q 2021)

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs

Aligos Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$6.10

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

Aligos Therapeutics, Inc. Receives Notice of A Complaint

Price target decreased to US$12.25

Aligos Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Price target decreased to US$19.20